ARCH, a venture capital firm, and 8VC, an investment company, led a $625m Series D round in Resilience, a technology-focused biomanufacturing company, with participation from NEA and Google Ventures. “We have an ambitious goal to reinvent biomanufacturing by bringing new processes and technologies to an industry that hasn’t kept pace with the explosive innovation in drug discovery. While we recognize that our goal is neither quick nor easy, we are driven by our mission to democratize access to medicines. These new funds will help support our next phase of growth, as we continue to innovate biomanufacturing across all our modalities, expand our footprint to serve customers, sign strategic collaborations and support the developers of a new generation of complex medicines,” Rahul Singhvi, Resilience Chief Executive Officer.